Showing results (281-290 of 304) with videos related to

Sort By:
Pageof 31
Lancet (London, England)|April 27, 1999
Screening for ovarian cancer: a pilot randomised controlled trialI J Jacobs, S J Skates, N MacDonald, et al.
The Journal of Clinical Endocrinology and Metabolism|September 22, 2000
Insulin-like growth factor I and the development of colorectal neoplasia in acromegalyP J Jenkins, V Frajese, A M Jones, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 1999
Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumorsK Lidhar, M Korbonits, S Jordan, et al.
Science (New York, N.Y.)|December 22, 1989
Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactionsM A Gimbrone, M S Obin, A F Brock, et al.
British Journal of Cancer|August 22, 2002
A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancerP O Van Trappen, A Ryan, M Carroll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumorsJeany M Rademaker-Lakhai, Catherine Terret, Stephen B Howell, et al.
Lancet (London, England)|February 24, 2001
Molecular quantification and mapping of lymph-node micrometastases in cervical cancerP O Van Trappen, V G Gyselman, D G Lowe, et al.
Clinical Endocrinology|April 25, 2001
Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegalyF Miraki-Moud, P J Jenkins, P D Fairclough, et al.
European Journal of Human Genetics : EJHG|April 1, 2004
Linkage disequilibrium in young genetically isolated Dutch populationYurii S Aulchenko, Peter Heutink, Ian Mackay, et al.
Breast Cancer Research and Treatment|November 30, 2019
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancerAnouk K M Claessens, Reinier Timman, Jan J Busschbach, et al.
Pageof 31